Jackson Creek Investment Advisors LLC Acquires 114 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Jackson Creek Investment Advisors LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,742 shares of the biotechnology company’s stock after buying an additional 114 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in United Therapeutics were worth $967,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of UTHR. World Investment Advisors LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $139,206,000. FMR LLC increased its holdings in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the last quarter. AustralianSuper Pty Ltd increased its holdings in United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after purchasing an additional 161,751 shares during the last quarter. Assetmark Inc. lifted its stake in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after buying an additional 152,249 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Price Performance

UTHR opened at $315.91 on Friday. The company has a market capitalization of $14.19 billion, a price-to-earnings ratio of 13.87, a P/E/G ratio of 0.97 and a beta of 0.57. The business’s 50-day moving average price is $355.41 and its two-hundred day moving average price is $360.08. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business posted $4.36 EPS. Sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 116,464 shares of company stock valued at $42,396,244 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.